ACTU

Actuate Therapeutics Inc.

MTD beats Q4 estimates as adjusted EPS jumps 8% Y/Y and sales rise to $1.13B, led by solid growth across Laboratory, Industrial and Food Retail.

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 529,786...

Wall Street Zen downgraded Actuate Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher - Time to Buy...

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Voss Capital LP grew its position in Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 101.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 286,140...

The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BIOS Capital Management LP raised its stake in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F...

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Actuate Therapeutics in a research report issued on Wednesday...